Risperidone oral solution

DRUG4 trials

Sponsors

Children's Hospital Medical Center, Cincinnati, Janssen Pharmaceutica N.V., Belgium, Central South University, Helsinki University Central Hospital

Conditions

Bipolar DisorderConduct DisorderDisruptive Behavior DisorderFood-drug InteractionOppositional Defiant DisorderPsychosisSchizophrenia

Phase 1

KF2022#3-trial: Effect of Tea and Cola Beverage on Absorption of Risperidone Oral Solution

CompletedNCT06218979

Helsinki University Central HospitalFood-drug Interaction, Psychosis

Start: 2023-12-08End: 2024-03-14Updated: 2024-12-05

Phase 3

Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders

CompletedNCT00221403

Children's Hospital Medical Center, CincinnatiBipolar Disorder

Start: 2004-09-30End: 2011-05-31Updated: 2020-10-20

A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation

CompletedNCT00250354

Janssen Pharmaceutica N.V., BelgiumConduct Disorder, Disruptive Behavior Disorder, Oppositional Defiant Disorder

Start: 1997-09-30End: 1999-08-31Updated: 2011-01-24

Phase 4

Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in Schizophrenia

CompletedNCT00859872

Central South UniversitySchizophrenia

Start: 2008-08-31End: 2009-03-31Updated: 2009-08-03